MDPI and ACS Style
Chae, H.; Sim, S.H.; Kwon, Y.; Lee, E.-G.; Han, J.H.; Jung, S.-Y.; Lee, S.; Kang, H.-S.; Kim, Y.-J.; Kim, T.H.;
et al. Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI). Cancers 2024, 16, 3122.
https://doi.org/10.3390/cancers16183122
AMA Style
Chae H, Sim SH, Kwon Y, Lee E-G, Han JH, Jung S-Y, Lee S, Kang H-S, Kim Y-J, Kim TH,
et al. Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI). Cancers. 2024; 16(18):3122.
https://doi.org/10.3390/cancers16183122
Chicago/Turabian Style
Chae, Heejung, Sung Hoon Sim, Youngmi Kwon, Eun-Gyeong Lee, Jai Hong Han, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Yeon-Joo Kim, Tae Hyun Kim,
and et al. 2024. "Neoadjuvant Chemotherapy with Concurrent Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast Cancer: An Open-Label, Single-Center, Nonrandomized Phase II Study (NeoCHAI)" Cancers 16, no. 18: 3122.
https://doi.org/10.3390/cancers16183122